Oruka Therapeutics

ORKA · Nasdaq · United States

Share price · ORKA

$95.74-17.34 (-15.33%) 3M

close as of 2026-11-18 · 24h delayed · vol 522K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ORKA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+4.7%

    Nothing announced by ORKA that day or the session before.

  2. 26 Oct 2026+12.7%
  3. 15 Oct 2026-3.7%
  4. 30 Jul 2026+11.1%
  5. 17 Jul 2026+11.6%
  6. 2 Jul 2026-8.7%

    Nothing announced by ORKA that day or the session before.

  7. 22 Jun 2026+18.0%
  8. 27 Apr 2026+10.7%
  9. 13 Mar 2026+25.0%
  10. 12 Jan 2026+10.2%

    Nothing announced by ORKA that day or the session before.

Share of unusual movement by asset

For each asset, the share of ORKA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Avrukibart
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—14%
Sessions with no dated event—83%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
IL-23 p19Monoclonal antibody
Psoriasis
Phase 2
IL-17A/FMonoclonal antibody
PsoriasisHidradenitis Suppurativa

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
ORKA-002Phase 2Plaque Psoriasis
Est. primary completion 2027-10 · NCT07474792 · CT.gov ↗
What to watch
2028 (1)
October 2028 (1)
ORKA-002Phase 2Hidradenitis Suppurativa (HS)
Est. primary completion 2028-10 · NCT07783542 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
ORKA-002Phase 2Plaque Psoriasis
Est. primary completion 2029-07-01 · NCT07933783 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
AvrukibartPhase 2Plaque Psoriasis
Est. primary completion 2030-05 · NCT07449702 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 October 2026Topline resultAvrukibartEVERLAST-B Phase 2b Week 16 topline results for ORKA-001
27 April 2026Topline resultORKA-001EVERLAST-A Phase 2a (NCT07090330) met its Week 16 PASI 100 primary endpoint
US · Oruka Therapeutics · Source ↗
27 April 2026Topline resultAvrukibartORKA-001 Week 16 interim results from EVERLAST-A Phase 2a

Financial reports

Quarterly & interim (19)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$54M$192M+ $729M short-term inv.$50M-$44M operating cash flowreport ↗
View 18 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$43M$268M+ $605M short-term inv.$41M-$33M operating cash flowreport ↗
2026-Q1—$29M$50M+ $339M short-term inv.$32M-$24M operating cash flowreport ↗
2025-Q3—$29M$91M+ $258M short-term inv.$30M-$22M operating cash flowreport ↗
2025-Q2—$24M$65M+ $263M short-term inv.$25M-$23M operating cash flowreport ↗
2025-Q1—$20M$84M+ $266M short-term inv.$21M-$21M operating cash flowreport ↗
2024-Q3—$26M$411M$29M-$28M operating cash flowreport ↗
2024-Q2—$0.1M$33M$2.7M-$2.6M operating cash flowreport ↗
2024-Q1$0$0.2M$36M$2.0M-$1.5M operating cash flowreport ↗
2023-Q4——$37M$1.1M-$1.1M operating cash flowreport ↗
2023-Q3—$0.3M$38M$1.4M-$1.7M operating cash flowreport ↗
2023-Q2—$0.3M$40M$1.5M-$0.7M operating cash flowreport ↗
2023-Q1$0$0.4M$41M$1.4M-$1.6M operating cash flowreport ↗
2022-Q4——$42M$1.2M-$1.5M operating cash flowreport ↗
2022-Q3—$1.0M$44M$2.3M-$2.5M operating cash flowreport ↗
2022-Q2—$1.5M$46M$3.1M-$2.6M operating cash flowreport ↗
2022-Q1$0$2.2M$49M$3.3M-$4.3M operating cash flowreport ↗
2021-Q4——$53M$5.7M-$5.0M operating cash flowreport ↗
2021-Q3—$3.4M$58M$4.7M-$4.9M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$101M$47M+ $290M short-term inv.$26M-$88M operating cash flowreport ↗

For fiscal year 2025, Oruka Therapeutics reported no disclosed revenue, R&D spend of $100.64M, cash and equivalents of $46.94M, and a net loss of $105.43M. The company’s quarterly net burn was $105.43M.

Oruka is advancing clinical-stage antibody programs for inflammatory diseases. ORKA-001, targeting IL-23p19, showed Phase 1 interim results with a human half-life of approximately 100 days and sustained STAT3 inhibition through 24 weeks; the Phase 2a EVERLAST-A trial is expected to report Week 16 data in the second quarter of 2026, and the Phase 2b EVERLAST-B trial, with first patients dosed in December 2025, has data anticipated in 2027. ORKA-002, targeting IL-17A/F, showed a Phase 1 interim half-life of approximately 75-80 days, and the Phase 2 ORCA-SURGE trial was initiated in February 2026 with data anticipated in 2027, alongside a planned Phase 2 trial in hidradenitis suppurativa in the second half of 2026. No financial guidance was provided.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY——$62M+ $314M short-term inv.$21Mreport ↗
2023-FY$0$1.0M$37M$1.3M-$5.0M operating cash flowreport ↗
2022-FY$0$4.8M$42M$2.5M-$11M operating cash flowreport ↗
2021-FY$0$14M$53M$4.8M-$19M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 145 sales ($343.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Goncalves Joana · Chief Medical OfficerOption exercise3,500$6.84$24KForm 4
2026-11-16Goncalves Joana · Chief Medical OfficerOption exercise3,500$7.80$27KForm 4
2026-11-16Goncalves Joana · Chief Medical OfficerOpen-market sale2,600$99.52$259KForm 4
2026-11-16Goncalves Joana · Chief Medical OfficerOpen-market sale1,500$100.48$151KForm 4
2026-11-16Goncalves Joana · Chief Medical OfficerOpen-market sale1,900$101.53$193KForm 4
2026-11-16Goncalves Joana · Chief Medical OfficerOpen-market sale300$102.47$31KForm 4
2026-11-16Goncalves Joana · Chief Medical OfficerOpen-market sale200$103.36$21KForm 4
2026-11-16Goncalves Joana · Chief Medical OfficerOpen-market sale500$105.86$53KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 184 reporting institutions held 52.9M shares ($2.6B, 78.0% of shares outstanding).

#InstitutionSharesValue
1FMR LLC7,431,403$364.5M
2Venrock Adviser, LLC4,148,428$203.5M
3Fairmount Funds Management LLC3,705,262$181.7M
4BlackRock, Inc.3,527,087$173.0M
5VIKING GLOBAL INVESTORS LP2,666,690$130.8M
6Paradigm Biocapital Advisors LP2,320,316$113.8M
7RTW INVESTMENTS, LP2,058,148$101.0M
8Deep Track Capital, LP2,034,203$99.8M
9VANGUARD CAPITAL MANAGEMENT LLC1,859,631$91.2M
10Avidity Partners Management LP1,520,848$89.3M
11STATE STREET CORP1,613,461$79.1M
12Remedium Capital Partners, LLC1,565,661$76.8M
13PERCEPTIVE ADVISORS LLC1,395,501$68.4M
14Polar Capital Holdings Plc1,047,693$51.4M
15CITADEL ADVISORS LLC1,007,537$49.4M